세계의 올리고뉴클레오티드 합성 시장 : 시장 규모, 점유율, 동향 분석(제품별, 용도별, 최종 용도별, 지역별), 부문별별 예측(2025-2030년)

Oligonucleotide Synthesis Market Growth & Trends:

The global oligonucleotide synthesis market size is expected to reach USD 8.83 billion by 2030, registering a CAGR of 13.2% from 2025 to 2030, according to a new report by Grand View Research, Inc. The strong pipeline of oligonucleotide therapeutics in clinical trials, advancements in gene editing technologies, and increasing R&D spending by biotechnology companies are some of the major factors driving the market growth.

Oligonucleotide therapeutics participants are present in the late stages of clinical trials and are expected to be approved & commercialized over the forecast period. Companies have increased investments to develop oligonucleotide-based therapeutics. In October 2023, GSK plc and Arrowhead Pharmaceuticals announced a contract with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson company, to assign GSK exclusive worldwide rights to develop and commercialize JNJ-3989. Janssen initially in-licensed JNJ-3989 (previously ARO-HBV) from Arrowhead in 2018. Similar initiatives by well-established pharmaceutical companies are anticipated to drive market growth over the forecast period.

Government bodies, such as the Centers for Medicaid & Medicare Services for labs, the Federal Trade Commission for marketing, and the FDA for kits & information, have played a key role in the success of genomics, as they have been involved in monitoring the safe, appropriate, and accurate application of genomics & genetic tests. International funding bodies, such as NIH and Wellcome Trust, are engaged in providing funds for genetic studies, which is expected to fuel genomic studies in developed and emerging economies.

In May 2021, the UK government announced a funding of USD 43.4 million (GBP 37 million) for genomics research and data-driven initiatives, delivered via the UK Functional Genomics Initiative and Genome UK Implementation Plan, which was started in September 2019. The Genome UK strategy will be implemented with the help of the Genomics England project, which will receive USD 19.9 million (GBP 17 million) to investigate the potential value of newborn sequencing.

Oligonucleotide Synthesis Market Report Highlights:

• The services segment dominated the oligonucleotide synthesis market, accounting for the largest revenue share of 31.5% in 2024. The oligonucleotides segment is expected to grow at a significant CAGR of 13.0% over the forecast period.
• PCR primers led the oligonucleotide synthesis industry with the largest revenue share in 2024. The sequencing segment is expected to grow at the fastest CAGR over the forecast period.
• The academic research institutes dominated the oligonucleotide synthesis market with the largest revenue share in 2024. The pharmaceutical and biotechnology companies segment is expected to grow significantly over the forecast period.
• The North America oligonucleotide synthesis market dominated the oligonucleotide synthesis industry with the largest revenue share of 31.9% in 2024. The Asia Pacific oligonucleotide synthesis market is expected to grow at the fastest CAGR of 14.9% over the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Application
  • 1.2.3. End Use
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Oligonucleotide Synthesis Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis

Chapter 4. Oligonucleotide Synthesis Market: Product Business Analysis

• 4.1. Product Market Share, 2024 & 2030
• 4.2. Product Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
• 4.4. Oligonucleotides
  • 4.4.1. Oligonucleotides Market, 2018 - 2030 (USD Million)
  • 4.4.2. Product Type
    • 4.4.2.1. Product Type Market, 2018 - 2030 (USD Million)
    • 4.4.2.2. Column-based Oligos
      • 4.4.2.2.1. Column-based Oligos Market, 2018 - 2030 (USD Million)
    • 4.4.2.3. Array-based Oligos
      • 4.4.2.3.1. Array-based Oligos Market, 2018 - 2030 (USD Million)
  • 4.4.3. Nucleic Acid Type
    • 4.4.3.1. Nucleic Acid Type Market, 2018 - 2030 (USD Million)
    • 4.4.3.2. DNA
      • 4.4.3.2.1. DNA Market, 2018 - 2030 (USD Million)
    • 4.4.3.3. RNA
      • 4.4.3.3.1. RNA Market, 2018 - 2030 (USD Million)
• 4.5. Equipment/Synthesizer
  • 4.5.1. Equipment/Synthesizer Market, 2018 - 2030 (USD Million)
• 4.6. Reagents
  • 4.6.1. Reagents Market, 2018 - 2030 (USD Million)
• 4.7. Services
  • 4.7.1. Services Market, 2018 - 2030 (USD Million)
  • 4.7.2. Oligo Synthesis
    • 4.7.2.1. Oligo Synthesis Market, 2018 - 2030 (USD Million)
    • 4.7.2.2. 25 nmol
      • 4.7.2.2.1. 25 nmol Market, 2018 - 2030 (USD Million)
    • 4.7.2.3. 50 nmol
      • 4.7.2.3.1. 50 nmol Market, 2018 - 2030 (USD Million)
    • 4.7.2.4. 200 nmol
      • 4.7.2.4.1. 200 nmol Market, 2018 - 2030 (USD Million)
    • 4.7.2.5. 1000nmol
      • 4.7.2.5.1. 1000nmol Market, 2018 - 2030 (USD Million)
    • 4.7.2.6. 10,000 nmol
      • 4.7.2.6.1. 10,000 nmol Market, 2018 - 2030 (USD Million)
  • 4.7.3. Purification
    • 4.7.3.1. Purification Market, 2018 - 2030 (USD Million)
  • 4.7.4. Modification
    • 4.7.4.1. Modification Market, 2018 - 2030 (USD Million)

Chapter 5. Oligonucleotide Synthesis Market: Application Business Analysis

• 5.1. Application Market Share, 2024 & 2030
• 5.2. Application Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 5.4. PCR Primers
  • 5.4.1. Oligonucleotide Synthesis Market, in PCR Primers, 2018 - 2030 (USD Million)
• 5.5. PCR Assays and Panels
  • 5.5.1. Oligonucleotide Synthesis Market, in PCR Assays and Panels, 2018 - 2030 (USD Million)
• 5.6. Sequencing
  • 5.6.1. Oligonucleotide Synthesis Market, in Sequencing, 2018 - 2030 (USD Million)
• 5.7. DNA Microarrays
  • 5.7.1. Oligonucleotide Synthesis Market, in DNA Microarrays, 2018 - 2030 (USD Million)
• 5.8. Fluorescence In Situ Hybridization (FISH)
  • 5.8.1. Oligonucleotide Synthesis Market, in Fluorescence In Situ Hybridization (FISH), 2018 - 2030 (USD Million)
• 5.9. Antisense Oligonucleotides
  • 5.9.1. Oligonucleotide Synthesis Market, in Antisense Oligonucleotides, 2018 - 2030 (USD Million)
• 5.10. Other Applications
  • 5.10.1. Oligonucleotide Synthesis Market, in Other Applications, 2018 - 2030 (USD Million)

Chapter 6. Oligonucleotide Synthesis Market: End Use Business Analysis

• 6.1. End Use Market Share, 2024 & 2030
• 6.2. End Use Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 6.4. Academic Research Institutes
  • 6.4.1. Oligonucleotide Synthesis Market, in Academic Research Institutes, 2018 - 2030 (USD Million)
• 6.5. Diagnostic Laboratories
  • 6.5.1. Oligonucleotide Synthesis Market, in Diagnostic Laboratories, 2018 - 2030 (USD Million)
• 6.6. Pharmaceutical and Biotechnology Companies
  • 6.6.1. Oligonucleotide Synthesis Market, in Pharmaceutical and Biotechnology Companies, 2018 - 2030 (USD Million)

Chapter 7. Oligonucleotide Synthesis Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.4. North America
  • 7.4.1. North America Oligonucleotide Synthesis Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 7.4.2. U.S.
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Regulatory Framework
    • 7.4.2.3. Competitive Insights
    • 7.4.2.4. U.S. Oligonucleotide Synthesis Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.4.3. Canada
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Regulatory Framework
    • 7.4.3.3. Competitive Insights
    • 7.4.3.4. Canada Oligonucleotide Synthesis Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.4.4. Mexico
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Regulatory Framework
    • 7.4.4.3. Competitive Insights
    • 7.4.4.4. Mexico Oligonucleotide Synthesis Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 7.5. Europe
  • 7.5.1. Europe Oligonucleotide Synthesis Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 7.5.2. Germany
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Regulatory Framework
    • 7.5.2.3. Competitive Insights
    • 7.5.2.4. Germany Oligonucleotide Synthesis Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.3. UK
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Regulatory Framework
    • 7.5.3.3. Competitive Insights
    • 7.5.3.4. UK Oligonucleotide Synthesis Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Regulatory Framework
    • 7.5.4.3. Competitive Insights
    • 7.5.4.4. France Oligonucleotide Synthesis Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Regulatory Framework
    • 7.5.5.3. Competitive Insights
    • 7.5.5.4. Italy Oligonucleotide Synthesis Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.6. Spain
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Regulatory Framework
    • 7.5.6.3. Competitive Insights
    • 7.5.6.4. Spain Oligonucleotide Synthesis Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.7. Denmark
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Regulatory Framework
    • 7.5.7.3. Competitive Insights
    • 7.5.7.4. Denmark Oligonucleotide Synthesis Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.8. Sweden
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Regulatory Framework
    • 7.5.8.3. Competitive Insights
    • 7.5.8.4. Sweden Oligonucleotide Synthesis Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.9. Norway
    • 7.5.9.1. Key Country Dynamics
    • 7.5.9.2. Regulatory Framework
    • 7.5.9.3. Competitive Insights
    • 7.5.9.4. Norway Oligonucleotide Synthesis Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific Oligonucleotide Synthesis Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 7.6.2. China
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Regulatory Framework
    • 7.6.2.3. Competitive Insights
    • 7.6.2.4. China Oligonucleotide Synthesis Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6.3. India
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Regulatory Framework
    • 7.6.3.3. Competitive Insights
    • 7.6.3.4. India Oligonucleotide Synthesis Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6.4. Japan
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Regulatory Framework
    • 7.6.4.3. Competitive Insights
    • 7.6.4.4. Japan Oligonucleotide Synthesis Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6.5. Australia
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Regulatory Framework
    • 7.6.5.3. Competitive Insights
    • 7.6.5.4. Australia Oligonucleotide Synthesis Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6.6. South Korea
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Regulatory Framework
    • 7.6.6.3. Competitive Insights
    • 7.6.6.4. South Korea Oligonucleotide Synthesis Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6.7. Thailand
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Regulatory Framework
    • 7.6.7.3. Competitive Insights
    • 7.6.7.4. Thailand Oligonucleotide Synthesis Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 7.7. Latin America
  • 7.7.1. Latin America Oligonucleotide Synthesis Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Regulatory Framework
    • 7.7.2.3. Competitive Insights
    • 7.7.2.4. Brazil Oligonucleotide Synthesis Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Regulatory Framework
    • 7.7.3.3. Competitive Insights
    • 7.7.3.4. Argentina Oligonucleotide Synthesis Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 7.8. Middle East & Africa
  • 7.8.1. Middle East & Africa Oligonucleotide Synthesis Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Regulatory Framework
    • 7.8.2.3. Competitive Insights
    • 7.8.2.4. South Africa Oligonucleotide Synthesis Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Regulatory Framework
    • 7.8.3.3. Competitive Insights
    • 7.8.3.4. Saudi Arabia Oligonucleotide Synthesis Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Regulatory Framework
    • 7.8.4.3. Competitive Insights
    • 7.8.4.4. UAE Oligonucleotide Synthesis Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Regulatory Framework
    • 7.8.5.3. Competitive Insights
    • 7.8.5.4. Kuwait Oligonucleotide Synthesis Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Participant Overview
• 8.2. Company Market Position Analysis
• 8.3. Company Categorization
• 8.4. Strategy Mapping
• 8.5. Company Profiles/Listing
  • 8.5.1. Thermo Fisher Scientific Inc.
    • 8.5.1.1. Overview
    • 8.5.1.2. Financial Performance
    • 8.5.1.3. Type Benchmarking
    • 8.5.1.4. Strategic Initiatives
  • 8.5.2. Merck KGaA
    • 8.5.2.1. Overview
    • 8.5.2.2. Financial Performance
    • 8.5.2.3. Type Benchmarking
    • 8.5.2.4. Strategic Initiatives
  • 8.5.3. Danaher
    • 8.5.3.1. Overview
    • 8.5.3.2. Financial Performance
    • 8.5.3.3. Type Benchmarking
    • 8.5.3.4. Strategic Initiatives
  • 8.5.4. Revvity Discovery Limited
    • 8.5.4.1. Overview
    • 8.5.4.2. Financial Performance
    • 8.5.4.3. Type Benchmarking
    • 8.5.4.4. Strategic Initiatives
  • 8.5.5. Agilent Technologies, Inc.
    • 8.5.5.1. Overview
    • 8.5.5.2. Financial Performance
    • 8.5.5.3. Type Benchmarking
    • 8.5.5.4. Strategic Initiatives
  • 8.5.6. Bio-Synthesis, Inc.
    • 8.5.6.1. Overview
    • 8.5.6.2. Financial Performance
    • 8.5.6.3. Type Benchmarking
    • 8.5.6.4. Strategic Initiatives
  • 8.5.7. Kaneka Eurogentec S.A.
    • 8.5.7.1. Overview
    • 8.5.7.2. Financial Performance
    • 8.5.7.3. Type Benchmarking
    • 8.5.7.4. Strategic Initiatives
  • 8.5.8. LGC Biosearch Technologies
    • 8.5.8.1. Overview
    • 8.5.8.2. Financial Performance
    • 8.5.8.3. Type Benchmarking
    • 8.5.8.4. Strategic Initiatives
  • 8.5.9. Biolegio
    • 8.5.9.1. Overview
    • 8.5.9.2. Financial Performance
    • 8.5.9.3. Type Benchmarking
    • 8.5.9.4. Strategic Initiatives
  • 8.5.10. Twist Bioscience
    • 8.5.10.1. Overview
    • 8.5.10.2. Financial Performance
    • 8.5.10.3. Type Benchmarking
    • 8.5.10.4. Strategic Initiatives